Home/Pipeline/GND-323

GND-323

Oncology

IND-EnablingActive

Key Facts

Indication

Oncology

Phase

IND-Enabling

Status

Active

Company

Gandeeva Therapeutics

About Gandeeva Therapeutics

AI‑driven cryo‑EM platform creates molecular glues for oncology targets.

View full company profile

Therapeutic Areas

Other Oncology Drugs

Drug	Company	Phase	Status
mRNA Anticancer Vaccine	Sunshine Biopharma	Preclinical Research	Active
Biosimilar Bevacizumab	Organon (2)	Phase 3	Active
Biosimilar Pembrolizumab	Organon (2)	Phase 3	Active
BCL-2 Inhibitor Program	Vincerx Pharma	Preclinical	Research
Attenukine Oncology Candidate	Teva	Phase 1	Active
XEMA Tumor Marker ELISA Kit	XEMA Group	Commercial	Active
KEAP1 Activator Program	Vividion Therapeutics	Phase 1	Active
Bendamustine Intermediate	AR Life Science	Commercial	Active
Imatinib Intermediate	AR Life Science	Commercial	Active
Dasatinib Intermediate	AR Life Science	Commercial	Active
Personalized Medicine Assays (Patient-Derived Explants)	Aurita Bioscience	Research-Use Only	Active
CDK2-CyclinE1 & CDK2-CyclinA2 Assay	Aurora Biolabs	Commercial	Available